The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations

Schizophrenia Research

Volumn 26, Issue 1, 1997, Pages 41-54

  Crawford, Ann Marie K ^a   Beasley Jr , Charles M ^a   Tollefson, Gary D ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antipsychotic; Atypical; Haloperidol; Olanzapine; Placebo; Prolactin

Indexed keywords

HALOPERIDOL; OLANZAPINE; PROLACTIN;

AMENORRHEA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GALACTORRHEA; HUMAN; HYPERPROLACTINEMIA; MALE; OSTEOPOROSIS; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; DOPAMINE ANTAGONISTS; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HUMANS; HYPERPROLACTINEMIA; LONGITUDINAL STUDIES; MALE; PIRENZEPINE; SCHIZOPHRENIA; SEX DISTRIBUTION; TIME FACTORS;

EID: 0030817163     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(97)00036-4     Document Type: Article

References (23)

1. Arnt, J., 1995. Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine. European Journal of Pharmacology 283, 55-62.
2. Barnes, T.R.E., 1989. A rating scale for drug-induced akathisia. British Journal of Psychiatry 154, 672-676.
3. Beasley, C., Tran, P., Tamura, R., Tollefson, G., 1995. Olanzapine versus haloperidol: results of the multi-center international trial. American College of Neuropsychopharmacology, San Juan, Puerto Rico.
4. Beasley, C., Tollefson, G., Tran, P., Satterlee, W., Sanger, T., Hamilton, S., 1996a. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14, 111-123.
5. Beasley, C., Sanger, T., Satterlee, W., Tollefson, G., Tran, P., Hamilton, S., 1996b. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 124, 159-167.
6. Bymaster, F.P., Calligaro, D.O., Falcone, J.F., March, R.D., Moore, N.A., Tye, N.C., Seeman, P., Wong, D.T., 1996a. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14, 87-96.
7. Bymaster, F.P., Hemrick-Luecke, S.K., Perry, K.W., Fuller, R.W., 1996b. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, α1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology 124, 87-94.
8. Cools, A.R., Prinssen, E.P.M., Ellenbroek, B.A., 1995. The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the paw test: effect of risperidone, prothipendyl, ORG 5222, sertindole, and olanzapine. Psychopharmacology 119, 428-439.
9. Fuller, R.W., Snoddy, H.D., 1992. Neuroendocrine evidence for antagonism of serotonin and dopamine receptor by olanzapine (LY170053) and antipsychotic drug candidate. Research Communications in Chemical Pathology and Pharmacology 77, 87-93.
10. Hollister, L.E., 1983. Clinical Pharmacology of Psychotherapeutic Drugs, 2nd ed. Churchill Livingstone, New York, pp. 151-171.
11. Kane, J.M., Cooper, T.B., Sachar, E.J., Halpern, F.S., Bailine, S., 1981. Clozapine: plasma levels and prolactin response. Psychopharmacology 73, 184-187.
12. Leibenluft, E., Fiero, P.L., Rubinow, D.R., 1994. Effects of the menstrual cycle on dependent variables in mood disorder research. Archives of General Psychiatry 51, 761-781.
13. Masaoka, K., Kitazawa, M., Kumasaka, T., 1988. Pulsatile secretion of prolactin and luteinizing hormone and their synchronous relationship during the human menstrual cycle. Gynecological Endocrinology 2, 293-303.
14. Meltzer, H.Y., 1991. The mechanism of action of novel antipsychotic drugs. Schizophrenia Bulletin 17, 263-287.
15. Meltzer, H.Y., 1995. Atypical antipsychotic drugs. In: Bloom, F.E., Kupper, D.J. (Eds.), Psychopharmacology: The Fourth Generation of Progress. Raven Press, New York, pp. 1277-1286.
16. Meltzer, H.Y., Goode, D.J., Schyve, P.M., Young, M., Fang, V.S., 1979. Effect of clozapine on human serum prolactin levels. American Journal of Psychiatry 136 (12), 1550-1555.
17. Moore, N.A., Tye, N.C., Axton, M.S., Risius, F.C., 1992. The behavioral pharmacology of olanzapine, a novel 'atypical' antipsychotic agent. Journal of Pharmacology and Experimental Therapeutics 262, 545-551.
18. Robertson, G.S., Fibiger, H.C., 1996. Effects of olanzapine on regional C-Fos expression in rat forebrain. Neuropsychopharmacology 14, 105-110.
19. SAS Institute Inc., 1989. SAS/STAT User's Guide, Version 6, Fourth Edition, vols. 1 and 2. SAS Institute, Inc., Cary, NC.
20. Simpson, G.M., Angus, J.W.S., 1970. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica Supplementum 212, 11-19.
21. Stockton, M.E., Rasmussen, K., 1996a. Electrophysiological effects of olanzapine, a novel atypical antipsychotic on A9 and A10 dopamine neurons. Neuropsychopharmacology 14, 97-104.
22. Stockton, M.E., Rasmussen, K., 1996b. Olanzapine, a novel atypical antipsychotic, reverses d-amphetamine-induced inhibition of midbrain dopamine cells. Psychopharmacology 124, 50-56.
23. Waldstreicher, J., Duffy, J.F., Brown, E.N., Rogacz, S., Allan, J.S., Czeisler, C.A., 1996. Gender differences in the temporal organization of prolactin (PRL) secretion: evidence for a sleep-independent circadian rhythm of circulating PRL levels - a clinical research center study. Journal of Clinical Endocrinology and Metabolism 81 (4), 1483-1487.